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Complexes of DNA with fluorescent 
dyes are effective reagents 
for detection of autoimmune 
antibodies
Ivana Domljanovic1, Annika Carstens1, Anders Okholm2, Jørgen Kjems2, Christoffer Tandrup 
Nielsen3, Niels H. H. Heegaard4,5 & Kira Astakhova1
To date, there are multiple assays developed that detect and quantify antibodies in biofluids. 
Nevertheless, there is still a lack of simple approaches that specifically detect autoimmune antibodies 
to double-stranded DNA. Herein we investigate the potential of novel nucleic acid complexes as targets 
for these antibodies. This is done in a simple, rapid and specific immunofluorescence assay. Specifically, 
employing 3D nanostructures (DNA origami), we present a new approach in the detection and study of 
human antibodies to DNA. We demonstrate the detection of anti-DNA antibodies that are characteristic 
of systemic lupus erythematosus, a chronic autoimmune disease with multiple manifestations. We 
tested the most potent non-covalent pairs of DNA and fluorescent dyes. Several complexes showed 
specific recognition of autoimmune antibodies in human samples of lupus patients using a simple 
one-step immunofluorescence method. This makes the novel assay developed herein a promising tool 
for research and point-of-care monitoring of anti-DNA antibodies. Using this method, we for the first 
time experimentally confirm that the disease-specific autoimmune antibodies are sensitive to the 3D 
structure of nucleic acids and not only to the nucleotide sequence, as was previously thought.
Human antibodies to nucleic acids have become ubiquitous as a tool in diagnostics and the study of autoimmune 
diseases1. This is the case in, for example, systemic lupus erythematosus (SLE)2. SLE is a systemic autoimmune 
disorder, potentially causing damage to any organ in the body via the abnormal response of the immune system to 
one’s own cells, tissues and biomolecules. The cause of SLE is not fully understood, but according to recent stud-
ies, anti-DNA antibodies play a crucial role by triggering the degradation of intracellular DNA after entrance into 
the cells3. Thus, in addition to anti-DNA autoantibodies being crucial for the diagnosis of SLE they are promising 
targets for therapy4. However, in spite of growing knowledge on anti-DNAs, there is still a lack of methods for 
their specific detection5.
Anti-DNAs are typically detected and quantified by immunoassays, such as enzyme-linked immunosorbent 
assay (ELISA) or Crithidia luciliae indirect immunofluorescence (IIF). Immunoassays are sensitive, versatile and 
simple methods that can detect and quantify targets in picomolar concentrations directly in complex biological 
media like serum6, 7. Many immunoassays can be run on very basic laboratory equipment, such as a microplate 
reader for ELISA8.
Although the assays are performed under equilibrium conditions, unfortunately they are unable to provide 
either any information on the structure of antigen–antibody complexes or quantitative binding characteristics8. 
Moreover, currently applied heterogeneous and unstable natural DNA molecules used as antigenic targets in 
these assays often result in poor reproducibility and low specificity of blood tests; around 5% of healthy persons 
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give a weakly positive result, even though they are not suffering from SLE2. Detected anti-DNA antibodies also 
cross-react with other antigens such as phospholipid cardiolipin2.
DNA binds to antibodies through hydrogen bonds, van der Waals and electrostatic forces8. Hydrophobic con-
tacts, together with the ion dipole bonds, contribute to the stability of protein-nucleic acid complexes, whereas 
hydrogen bonds with base edges are important for specificity9. Recently, we and others applied a computational 
approach to improve the understanding of DNA-antibody interactions9, 10. Y. An et al.10 showed that the mono-
clonal antibody ED-1011 interacts with two adjacent nucleotides in its binding site and favours dTdC over other 
nucleotides and that this recognition motif is highly prevalent in the polyclonal antibody species such as those 
present in SLE sera.
Besides antibodies, DNA uses similar types of interactions for binding to small molecules such as fluorescent 
dyes12. To date there is a plethora of fluorophores developed that bind DNA in a sequence-independent fashion. 
They share a similar structural motif of aromatic core that intercalates into the dsDNA and additional ‘arms’ that 
form stabilizing hydrogen bonds with the grooves13. Examples of this type include ethidium bromide, thiazole 
orange and acridine yellow. Another type of structure is presented by groove-binding dyes, such as Sybr Green 
and the recently developed analogue Eva Green14. Upon binding to DNA, the fluorescence of these dyes lights 
up 20-fold for Sybr Green and up to 130-fold for Eva Green. The light-up occurs due to the elimination of the 
quenching interactions of aromatic fluorophores with aqueous media when the dye is positioned within the stack 
and/or hydrophobic dsDNA grooves15. Besides high brightness, Eva Green has the advantage of low toxicity and 
therefore is an attractive dye for research and clinical diagnostics of dsDNA14.
Valuable structural information on a-DNAs can be gained through the use of sequence-defined synthetic 
antigens. Synthetic oligonucleotides may be produced with high purity, good specificity and affinity, and provide 
well-controlled chemical structures, which make them a promising tool for diagnostics and studies of autoim-
mune diseases where aberrant anti-DNA immunoreactivity occurs9. Recently we and others proved that rational 
design and the incorporation of modified nucleotides into oligonucleotides can provide valuable dsDNA antigens 
for ELISA of a-DNA9. Taking these recent works into account, DNA antigens can be divided into two classes: 
short synthetic DNA and large, mixmer biological structures. In most studies including our recent publication, 
both classes are used in indirect assay (Fig. 1). However the potential of using non-covalent complexes between 
these synthetic antigens and the aforementioned fluorophores as reagents for the detection and study of autoim-
mune antibodies has not been explored thus far.
In this work we aimed at studying synthetic DNA antigens of two types, short dsDNA and large DNA origami, 
in a direct immunofluorescence assay (Fig. 1). Our hypothesis was that the specific recognition of DNA by corre-
sponding antibodies displaces the number of fluorophores bound to it, which can be followed simply by fluorom-
etry. We show that antibodies to DNA are sensitive to nucleotide composition and chemical modification in short 
synthetic antigens. Our study also proves that DNA origami and Eva Green dye form ultra-bright non-covalent 
complexes that are useful in sensing a-DNAs in lupus sera. Having studied different origami structures, our data 
suggest that the 3D structure of DNA origami has an effect on the recognition of antibodies. In this study also we 
demonstrate that the novel immunofluorescence assay detects antibodies specific to SLE, enabling simple, time- 
and cost-effective diagnostics of clinically relevant antibodies.
Results
Patient samples used in this work: selection and characterization. For this work, we selected sera 
samples from 28 adults who were diagnosed with SLE (SSI, Denmark). SLE samples 1–8 have been used in our 
recent study9, whereas samples SLE 9–28 were from a new cohort. To investigate specificity of antibody detection 
we additionally chose monoclonal and polyclonal antibodies, and patient samples with a different autoimmune 
disease, rheumatoid arthritis (RA, samples 1–20, provided by SSI, Denmark). RA and SLE patients fulfilled the 
relevant American College of Rheumatology disease criteria16, 17. 57% SLE (SSI) were ANA positive.
For specificity studies, we included additional ANA positive SLE samples18 (n = 30; 100% ANA positive) 
which were analysed along with non-matched healthy control cohort from SSI (n = 20) and Odense University 
Hospital (OUH; n = 60), and non-matched disease-stated sera from OUH: Crohn’s disease19 (n = 10), RA 
(n = 30), antiphospholipid syndrome20 (APS, n = 30), hepatitis B21 (n = 4), and cancer22, 23 (n = 8). Rationale for 
Figure 1. (a) Molecular model for the interaction between dsDNA and monoclonal autoimmune antibody ED-
109–11; (b) Two types of the synthetic antigens used in this work: short synthetic DNA and 3D DNA origami.
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choosing these diseases as controls is that Crohn’s disease, RA and APS are autoimmune, whereas hepatitis B 
and cancer might raise a-DNA levels as well16–21, 24, 25. For the diagnosis establishment, patients fulfilled relevant 
disease criteria19–23.
All the samples have been characterized by clinical laboratory for the presence of autoimmune antibod-
ies. Additionally, we ran a-dsDNA ELISA using TC-rich antigen SEQ1. For extended OUH cohort, commer-
cial a-dsDNA ELISA kit was used as well (Supplementary Table S7). The results are shown in Supplementary 
Figure S1 and Table S7. As expected, 50–93% SLE samples showed elevated levels of a-dsDNA. In ELISA, RA and 
healthy controls showed weakly elevated a-dsDNA levels as well (10% RA (SSI), 10% healthy controls (SSI), 23% 
RA (OUH) and 28% healthy controls (OUH)). a-dsDNA positivity is not typical in RA26. Nevertheless 15–17% 
RA samples used herein were antinuclear antibody (ANA) positive, as evaluated by the commercially available 
ELISA test (Methods; Supplemental Figure S5, Table S7)27.
DNA 50mer antigens: interaction with fluorophores and autoimmune antibodies. To target 
antibodies in patient sera, we initially designed three oligonucleotides as 50mer double-stranded helixes with 
different sequences9, 28 (SEQ1-3; Methods, Table 1). SEQ1, SEQ2 and SEQ3 were different in terms of nucle-
obase composition, containing TC, T + C and mixmer ATCG nucleotides, where +C is a locked nucleic acid 
(LNA) modification. Based on our recent report9, these compositions are favourable for specific interaction with 
SLE-related antibodies. However, to enhance the interaction with the dyes we extended the sequences to 50mers 
vs previously used 21mers.
Next, we selected three fluorescent dyes that are well known for interacting with dsDNA: intercalating dyes 
thiazole orange (TO) and acridine yellow G (AYG), and minor groove-binding Eva Green EG (Fig. 2a). We 
studied the interaction of these dyes with dsDNA 1–3 using fluorometry. Each dye was added to the mixture 
of two complementary DNA strands and the resulting mixtures were annealed (see methods). As expected, all 
the dyes showed quenched fluorescence in aqueous media and lit up upon binding to dsDNA (Supplementary 
Sequence, 5′-3′ Length (nt)
SEQ1: (TCC TCT CTT TCT CTT TCT CTT TCC TCT CTT TCT CTT TCT CTT TCC 
TCT CT):(AGA GAG GAA AGA GAA AGA GAA AGA GAG GAA AGA GAA AGA 
GAA AGA GAG GA)
50
SEQ2: (TCC + TCT CTT TCT + CTT TCT + CTT TCC + TCT CTT TCT + CTT 
TCT + CTT TCC + TCT CT):(AGA GAG GAA AGA GAA AGA GAA AGA GAG 
GAA AGA GAA AGA GAA AGA GAG GA)
50
SEQ3: (TGA ACT CTA TGT CTG TAT CAT TGA ACT CTA TGT CTG TAT CAT 
TGA ACT CT):(AGA GTT CAA TGA TAC AGA CAT AGA GTT CAA TGA TAC 
AGA CAT AGA GTT CA)
50
SEQ4: (TCC TCT CTT TCT CTT TCT CTT):(AAG AGA AAG AGA AAG AGA GGA) 21
Table 1. Synthetic dsDNA used in this study*. *Pluses indicate LNA modifications.
Figure 2. (a) Chemical structures of fluorescent dyes used in this work; (b) Main principle of the direct 
immunofluorescence assay developed herein.
www.nature.com/scientificreports/
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Table S1). The brightest signal was observed for TO whereas the complexes of AYG and EG were 1.5–3-fold dim-
mer. Notably, the LNA rich sequence interacted less efficiently with the dyes and therefore was excluded from the 
study (Supplementary Table S1).
We applied SEQ1-dye complexes in an immunofluorescence assay (Fig. 2b). The rationale behind the assay 
was that the binding of an autoimmune antibody changes the number of dye molecules that are bound to DNA 
and also the micro-environmental parameters of the molecule. In particular, polarity and hydrophobicity are 
important for fluorescence intensity. We carried out the incubation of fluorescent DNA complex with control 
antibodies and patient sera for 1.5 hour at 37 °C, which is a physiologically the most relevant temperature29. Calf 
thymus DNA and single stranded synthetic DNA were used as controls9, 28. The result was detected by fluorometry 
as a change in the dye’s fluorescence intensity (Supplementary Figure S1). In the preliminary study of mono- and 
polyclonal antibodies SEQ1 and SEQ3 showed no binding of antibodies to β2-microglobulin, cardiolipin and 
HIV-1 protein associated antibody gp120 used as negative controls. Exclusively TO complex with LNA-modified 
SEQ2 showed a weak signal with anti-β2-microglobulin. On the contrary, calf thymus DNA (CTD) showed bind-
ing of all the negative controls, with the highest signal for anti-cardiolipin polyclonal antibodies. This was similar 
to the single-stranded controls SD1 and SD2 (Supplementary Table S2).
Next, using fluorescent complexes of SEQ1-3, we run the assay for eight SLE positive patient sera and 10 
healthy controls. Based on the results (shown in Supplemental Figure S1), we made several important observa-
tions. First, no signal change was observed when DNA was not present. Next, there was a big difference in the 
response for each dye and DNA sequence. AYG showed low sensitivity to interaction with SLE sera, whereas EG 
and TO showed 1.7–3.4 fold fluorescence increase. Importantly, we observed no signal change for EG and TO 
complexes with SEQ1-2 in the healthy controls. However, the signal change upon incubation was below the detec-
tion limit needed for diagnostic applications (3-fold above background of the microtiter plate). We conclude that 
the number of dyes interacting with antigens had to be increased in order to improve the sensitivity of antibody 
detection.
DNA origami as antigens for immunofluorescence assay. In the next step we hypothesized that 3D 
DNA nanostructures with their extended size and well-defined shape could be favourable for the binding of 
multiple fluorescent dyes and also for an effective interaction with antibodies in patient sera30, 31. To check this 
hypothesis we selected two DNA origami structures: a 100 nm × 70 nm 2D rectangle (TR) and six-helix bundle 
(6HB) rod approximately 400 nm in length. To prepare the origami structures and introduce fluorophores we used 
a thermal annealing protocol (methods). EG, TO and AYG were added in different concentrations at 60 °C. This 
was done in order to prevent dye degradation and ensure its successful incorporation into the nanostructure32.
We studied the obtained fluorescent origami complexes by fluorometry (Supplementary Figure S2). A striking 
finding was that TO did not show any difference in fluorescence upon incubation with origami, even when the 
protocol was changed and TO was added at 90 °C. On the contrary, EG showed the highest fluorescence with 
both structures, with a remarkable signal-to-background ratio of 30. Therefore we chose origami-EG complexes 
for further immunofluorescence assay. AYG was excluded due to low sensitivity to interaction with human sera 
mentioned above.
The dye concentration in the annealing mixture also had an interesting effect on the fluorescence properties 
of the complex. Approximately 0.5X EG solutions gave extremely bright fluorescent complexes. However, using 
more EG dye (1-2X), the fluorescence of the resulting nanostructure complexes was quenched 2-fold and more 
compared to the complexes with a more diluted dye (Supplemental Figure S3).
For immunofluorescence, complexes of TR and 6HB with EG dye in the optimal dilution regimen were incu-
bated with SLE sera and controls as described for 50mer duplexes (Supplemental Tables S3–S7). The resulting 
fluorescence intensity is shown in Figs 3 and 4. First, the background signal of Eva Green dye in the absence 
of origami did not differ from the background of empty microtiter plates (Fig. 3, EG group). Next, 50% SLE 
(SSI) and 93% SLE (OUH) had a positive signal upon incubation with the TR-EG complex (Fig. 4; Supplemental 
Tables S6, S7). Notably, only a few samples showed a positive signal when origami controls without the large 
bacteriophage DNA were applied. Furthermore, we also observed a difference in signal between the TR-EG and 
6HB-EG complexes. The difference in fluorescence intensity for all tested groups was statistically significant with 
p = 0.018 as confirmed by one-way ANOVA analysis in R (Methods)33. Lastly, using a different origami structure 
or excluding the bacteriophage sequence from it lead to statistically significant difference in response when the 
same patient samples were used (p = 0.07 and 0.04 for TR‒6HB and TR‒TR% groups).
Using healthy cohort, we additionally compared performance of TR-EG to calf thymus DNA-EG 
(Supplementary Table S2). In a good agreement with our recent study9, CTD showed a high number of false pos-
itive results in healthy controls (31%), which points on non-specific interactions.
Sensitivity and specificity of the developed assay to SLE were studied using additional patient samples 
obtained from OUH, Denmark (Supplementary Table S7). Being compared to the commercial a-dsDNA ELISA 
test, TR-EG immunofluorescence method showed superior specificity to SLE (94% vs. 81%), whereas the sen-
sitivity was similar for both assays (93%). In turn, when compared to SEQ1-ELISA, the specificity was similar, 
although the former method had slightly lower sensitivity to SLE (80% vs. 93%). Remarkably, the developed 
immunofluorescence assay showed lower number of positives in healthy controls when compared to ELISA (3% 
vs. 13% and 10% for immunofluorescence vs. commercial and in-house SEQ1-ELISA; n = 60). Number of pos-
itives in other rheumatic diseases (RA, APS) was also lower for IFA and SEQ1-ELISA than for the commercial 
a-dsDNA test (7–8% vs. 18%; Supplementary Table S7). In Crohn’s disease, hepatitis B and cancer, the perfor-
mance of TR-EG assay was slightly better than for SEQ1-ELISA (14% vs. 9%. positives), and superior to the 
commercial ELISA which gave 32% positives in these samples.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 1925  | DOI:10.1038/s41598-017-02214-0
As a final aspect, we explored the limitations and benefits of each assay format by a comparative study of the 
limit of target detection (LOD), cost, labour demand and speed (Fig. 5; see methods for details). The developed 
immunofluorescence using TR-EG complex had 10-times higher LOD than SEQ1-ELISA. However, immunoflu-
orescence was much faster, less expensive and less labour-intensive. This is accompanied by a higher stability of 
the origami reagents applied for immunofluorescence when compared to precoated ELISA plates (Fig. 5c). ROC 
curves are often used to compare specificity and sensitivity of the assays at different cut off values34. In agreement 
with close LOD values, receiver-operating characteristic (ROC) curves were rather similar for ELISA and immu-
nofluorescence assays (Supplemental Figure S6; Supplemental Table S8).
Figure 3. Immunofluorescence assay results using DNA origami and Eva Green and SLE sera. Cut-off values 
are shown as green lines; they were determined for each antigen as 2 standard deviations above the mean value 
for response in a non-matched healthy control cohort (n = 20). TR, 6HB = assembled DNA origami; TR%, 
6HB% = origami sequences without bacteriophage DNA. S1–S10 = SLE patient samples. EG = Eva Green.
Figure 4. Box-and-whisker plot with outliers for the results of ELISA and immunofluorescence assays 
performed for SSI samples: SLE (n = 28), HC (n = 20) and RA (n = 20). The arms on each boxplot are values 
Q1–1.5 × IQR and Q3 + 1.5 × IQR. Data points for each subject are means for three independent measurements. 
TR-EG = TR origami complex with Eva Green dye. Standard error bars for independent triplicate experiments 
(n = 3) across antigens are shown in Supplementary Figure S4.
www.nature.com/scientificreports/
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Discussion
The purpose of this work was to investigate the possibility of using sequence-controlled short DNA antigens and 
well-defined 3D DNA structures as new reagents that may have the potential to discriminate among anti-DNA 
antibodies and advance existing detection methods. As we demonstrate in this paper, using DNA origami and 
the minor groove-binding dye Eva Green, a fast immunofluorescence assay can be performed for the detection 
of antibodies towards dsDNA. The method takes advantage of the fact that the number of dyes interacting with 
DNA changes when the antibody interacts with the DNA-dye complex, Since fluorescence of the dye is quenched 
in aqueous media and increases in hydrophobic environments, such as the DNA groove or antibody epitope, the 
interaction between the dye-DNA and antibody can be traced by the fluorescent signal of the dye.
This work results in two major findings. First, the 3D structure of DNA has an impact on the interaction 
with disease-specific autoimmune antibodies. In particular, our studies confirm that the well-defined structure 
of DNA antigen is beneficial for the interaction with a-dsDNA of preferably the IgG type. This is also proved 
by the negative result of our control experiments when a simple mixture of origami primers is used as antigen. 
Second, the binding of fluorophores to large mixmer DNA origami ensures the generation of enough signal when 
a high-affinity antibody ‘removes’ the dye and interacts with the DNA antigen. This could not be achieved when 
using shorter dsDNA since not enough dye molecules were bound and therefore the signal upon antibody rec-
ognition was too weak. Thus, multiple interaction sites for the dye on the DNA origami act as a signal ‘booster’ 
for the assay, and hence allow a simple, single-step immunofluorescence homogeneous method to be carried out.
The interaction of diverse DNA antigens with fluorophores and consequent binding of polyclonal antibody 
targets by the DNA-dye complexes are fundamental interactions that we investigate in this work. An interesting 
finding is that intercalating and groove-binding dyes have different binding properties for short dsDNA and large 
nanostructures such as DNA origami. Short dsDNAs effectively bind the DNA intercalator thiazole orange and 
show less binding with groove-binding Eva Green. For DNA origami the situation is just the opposite: thiazole 
orange shows no interaction whereas Eva Green generates stable, bright complexes.
This work lies in the context of recent research on fluorescent DNA-protein interactions, although the reports 
on 3D DNA-protein interactions are limited, especially as tools for the diagnostics of autoimmune diseases. 
Recently, DNA nanostructures were proposed for the directed recognition of proteins35. The interaction of ori-
gami with antibodies has also been demonstrated before, although not in the context of diagnostics and the study 
of autoimmune diseases but for the detection of origami via ligand-specific aptamer sequence36.
Our assay shows that the structure of origami has an influence on the antibody binding. Thus, TR shows 
a bright positive signal and a statistically significant difference upon interaction with antibodies in SLE- and 
RA-positive sera, whereas for 6HB the overall signal is lower and there is no statistically significant difference in 
the signal for patient samples vs. controls. Once again, this implies that in addition to sequence specificity, the 3D 
structure of DNA antigen might have an influence on its recognition by the autoimmune antibodies37–39. This has 
been previously observed for small DNA, however the detailed structure of these DNA-antibody complexes has 
not been studied40. This could be due to the fact that NMR and X-ray studies of DNA complexes are experimen-
tally challenging41. This makes us believe that this new immunofluorescence assay has a high potential as a tool 
Figure 5. Comparison of SEQ1-ELISA and immunofluorescence assays: (a) limit of target detection 
determination. Signal at each point is a mean value for triplicate measurement of randomly selected 5 SLE 
samples; (b) (left to right) time, step count per one assay; cost per sample analysed, shelf-life time of antigen. 
Each measurement has been done three times with a result deviation ±3%.
www.nature.com/scientificreports/
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to gain new valuable knowledge on DNA-protein complexes, and in particular on clinically relevant autoimmune 
antibodies, as demonstrated in this paper.
Generally, the immunofluorescence assay proposed herein has comparable sensitivity and specificity to 
SLE as ELISA (81–93% and 80–94%), but 10-fold higher LOD. Nevertheless, a rather small amount of patient 
sera (2 µL per analysis) was sufficient for the detection of a-DNAs in SLE-positive sera. Notably, the developed 
method shows 10–15% of positives in RA, whereas ELISA gives 10–23% positives in RA. RA and SLE share sim-
ilar autoimmune features. Therefore it is expected that there is some overlap in the biomarker profiles of these 
diseases16–18. Additional tests needed to distinguish RA from SLE include complement components (C3, C4), 
erythrocyte sedimentation rate, cyclic citrullinated peptide antibody and rheumatoid factor42, 43.
It is advantageous that the length of the assay is reduced from 6.5 hr for indirect ELISA to only 1.5 hr, which 
is comparable to direct immunofluorescence assay (DIF)44. However, the cost of new immunofluorescence assay 
per sample is much lower than for ELISA and DIF since it does not require the use of expensive antibody reagents. 
Moreover, the origami reagent has a much longer shelf life (2 years at −20 °C and >5 years at −80 °C, vs. 4 month 
for pre-coated ELISA plates at +4 °C; see methods). Immunofluorescence is also way less labour-intensive and 
therefore could become a useful tool in the diagnostics of clinically and biologically relevant antibodies.
In conclusion, we show that disease-specific autoimmune antibodies can discriminate the 3D structure of 
macromolecular DNA antigens. We confirm improved specificity of synthetic double-stranded complexes com-
pared to currently applied CTD and single stranded DNA. We also demonstrate that non-covalent complexes, 
such as DNA origami with groove-binding dye, can be a useful tool in fast and specific detection of autoimmune 
antibodies. The biological role of 3D DNA structure in interactions with autoantibodies remains to be fully eluci-
dated. In this study, we have taken an initial step to facilitate this exploration and to provide a new tool that merits 
further exploration for assessment of DNA-binding antibodies in autoimmunity with potential for differentiating 
among distinct diseases.
Methods
General. Oligonucleotides SEQ1-3 (Table 1) were synthesised in-house using the phosphoramidite 
method45. All other nucleic acid compounds were obtained from Integrated DNA technologies, Inc., Iowa, USA. 
Fluorescence dyes were purchased from Sigma (AYG, TO) and Biotium (EG) and used as received. Calf thymus 
DNA (CTD) was purchased from Sigma (cat no. D1501).
ELISA assays were made manually using following the protocol described recently9. Commercial a-dsDNA 
ELISA kit was purchased from Abcam (cat. no. ab178618). Plates were analysed using a TECAN microplate 
reader and measuring absorbance at 450 nm. 96-well Maxisorb NUNC microplates were purchased from 
Thermofisher Scientific.
Patient sera samples and healthy controls were obtained from Odense University Hospital and Statens Serum 
Institute, Denmark. Monoclonal antibodies were provided by Statens Serum Institute, Denmark (anti-dsDNA 
and anti-β2-microglobulin), purchased from commercial supplier (anti-cardiolipin, Immunovision, cat no HCL-
0200; gp120 (Abcam, cat no ab21179). Written approval by The Danish Data Protection Agency was obtained 
in November 2015. Committee of Information Safety of the Region Southern Denmark at the Danish Data 
Protection Agency specifically approved the whole study (permission signed by Pernille Winther Christensen). 
The methods were carried out in accordance with the relevant guidelines and regulations as stated in the Act on 
Processing of Personal Data adopted by the Danish Data Protection Agency on June 2nd 2000. Personal data of 
patients was not used in this work. Therefore the informed consent from the individuals was not needed.
Price per assay has been estimated using costs for oligonucleotides, dyes, other reagents and equipment pro-
vided by commercial suppliers (IDT, Sigma).
Step count is determined using S health application (Samsung galaxy S5) as an average number of steps for an 
individual while performing the assay.
Antigen stability upon storage was determined by MALDI-MS and ELISA for synthetic ODNs and precoated 
plates, respectively.
50mer DNA Antigens and 21mer ELISA control. Sequences SEQ1-4 used in this study are shown in 
Table 1.
Origami sequences were designed and prepared following published procedures46, 47. Annealing procedure 
for origami and controls was carried out using 10 nM samples in 1x TAE buffer with 12 mM MgCl2 as follows: lid 
100 °C, 90 °C 2 min, 90–60 decrease 0, 5 °C pr 1 min, 60–50 decrease 0, 2 °C pr 10 min, 50–35 decrease 0, 5 °C pr 
1 min; store at RT or 10 °C.
ANA kit was purchased from Abcam (product no. ab178610) and used following manufacturer’s protocol.
General protocol for immunofluorescence assay. In a microplate, DNA-dye antigen (4 μL, 10 nM) was 
mixed with 4 μL freshly prepared diluent (1 g BSA, 200 μL Tween-20 in 1 L 1 × PBS). Afterwards 2 μL serum sam-
ple was added. Incubation was performed for 1.5 h at 37 °C, followed by immediate fluorescence detection at Light 
Cycler 480 reader (emission at 530 nm). Incubation time and volume were optimized by a series of experiments 
carried out for 30 min–2 hrs, using 2–50 μL incubaton reactions (see Supplemental information).
Data analysis was performed in R using one-way ANOVA33.
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